TRACON Pharmaceuticals (TCON)
(Delayed Data from OTC)
$0.09 USD
-0.03 (-27.65%)
Updated Aug 29, 2024 03:01 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
TRACON Pharmaceuticals, Inc. [TCON]
Reports for Purchase
Showing records 61 - 72 ( 72 total )
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q Recap -TRC105 and TRC102 Clinical Profile Expansion Contnues
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Another Validation for TRC105, Data from Four Phase 2''s Coming Up
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Intriguing Entry Point Ahead of Data Deluge
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Intriguing Play in the $16B Global Anti-VEGF Market-Initiate with Buy rating and $18 target
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D